Mary Fletcher Louis
We have lived through a sea change in market access. In the old world, ‘I tell you my price, and I sell you my drug’. In the new world, our pharmaceutical clients need to engage with patients, negotiate with payers, agree predefined sub-populations, define and articulate stakeholder-specific value stories, and then put in place the data capture schemes to meet the burden of proof. We are accompanying our clients on every step in that journey.”
Mary has worked for Decision Resources Group serving the pharmaceutical industry for 18 years. She started working with Decision Resources consulting team in 1997 analyzing the European healthcare systems in the days before ‘market access’ was coined. She subsequently joined our team of market analysts, leading and training our team of oncology experts to conduct literature reviews, design and execute primary research projects, and forecast the oncology markets.
In 2005, Mary achieved a distinction in her MPH (advanced statistics, epidemiology), and went on to run DRG's first payer research product. Initially focusing on success factors for favorable reimbursement of pharmaceuticals in the United States, Mary expanded the portfolio to explore reimbursement of pharmaceuticals in Europe and key emerging markets. In this role, Mary has lead projects across multiple indications, identifying brand-specific value messages that drive payer and prescriber behavior in the EU5, US and LATAM healthcare systems.
Drawing upon European payer research, Mary led a team running EU market access training workshops in 9 major European Pharma company HQs.
Since 2013, Mary’s role in DRG has been to direct and execute strategy and investment for DRG’s US and global pricing and reimbursement portfolio. This role gave Mary the opportunity to work closely with our clients to ensure that our offerings are evolved to meet their business needs.
In 2014, Mary worked with Abacus International to establish an HTA insight tool covering HTA decisions in 14 countries and 22 HTA agencies. The tool analyzes the drivers of HTA success across metabolic disorders (including diabetes), as well as immune diseases, cardiovascular disorders, and oncology.
Prior to her time with DRG Mary worked for Oxfam and for Amnesty International.